Solos Endoscopy Reports Financial Results for Period Ended December 31, 2013
April 01 2014 - 10:05AM
Marketwired
Solos Endoscopy Reports Financial Results for Period Ended December
31, 2013
BOSTON, MA--(Marketwired - Apr 1, 2014) - Solos Endoscopy, Inc.
(OTC Pink: SNDY) (PINKSHEETS: SNDY), a provider of quality
innovative healthcare instruments to hospitals across the United
States, reported sales and earnings results for the period ended
December 31, 2013.
The Company posted its
financial results and disclosure statement on the OTC Markets
website (http://www.otcmarkets.com/stock/SNDY/filings).
Solos Endoscopy recently
received its ISO 13485:2003 Certification from TUV SUD America. The
Certification to ISO 13485:2003 allows Solos Endoscopy to place the
CE Mark on the majority of endoscopic instruments including the
MammoView® devices. Solos Endoscopy announced that the company has
commenced negotiations with a Canadian distributor to sell its
endoscopic instruments including the MammoView® devices in
Canada.
The Certification Body of TUV
America has certified that Solos Endoscopy has established and is
maintaining a quality management system that meets the requirements
of the European Union and Canada. The Certification comes at the
conclusion of a lengthy Audit with TUV SUD America this past Year.
The Audit included a comprehensive review of the Solos Endoscopy's
Quality Manual and 28 Quality System Procedures for compliance with
the international quality system standard ISO 13485:2003, to the
European Union's Medical Device Directive (MDD 93/42/EEC) and to
the Canadian Medical Device Regulations (SOR/98-282).
Solos Endoscopy has posted its Certificate from TUV America on
its website
(http://www.solosendoscopy.com/pdf/solos-iso-certification.pdf).
About Solos Endoscopy, Inc.:
Solos Endoscopy has celebrated its 25th year of providing
quality innovative healthcare instruments to hospitals across the
country. For more than 25 years, from medical schools to hospitals,
surgeons have trusted Solos Endoscopy to develop and market
breakthrough technology, applications, medical devices, and
procedural techniques for the screening, diagnosis, treatment and
management of disease and medical conditions. Additional
information on its FDA approved products is available on the
Company's website at: www.solosendoscopy.com.
Certain statements in this news release may contain
forward-looking information within the meaning of Rule 175 under
the Securities Act of 1933 and Rule 3b-6 under the Securities
Exchange Act of 1934, and are subject to the safe harbor created by
those rules. All statements, other than statements of fact,
included in this release, including, without limitation, statements
regarding potential future plans and objectives of the company, are
forward-looking statements that involve risks and uncertainties.
There can be no assurance that such statements will prove to be
accurate and actual results and future events could differ
materially from those anticipated in such statements. Technical
complications that may arise could prevent the prompt
implementation of any strategically significant plan(s) outlined
above. The company cautions that these forward-looking statements
are further qualified by other factors including, but not limited
to, those set forth in the company's Annual Report filing and other
filings with the OTC Markets Group (available at
www.otcmarkets.com). The company undertakes no obligation to
publicly update or revise any statements in this release, whether
as a result of new information, future events, or otherwise.
Solos Endoscopy, Inc. Investor Relations (617) 360-9719